India, Oct. 24 -- Roche (RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically significant and clinically meaningful reduction in proteinuria in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care.
Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 showed that patients treated with sefaxersen achieved a 43.1% reduction in proteinuria relative to placebo at Week 37, as measured by the 24-hour urine protein-to-creatinine ratio (UPCR), the study's primary endpoint.
Proteinuria, or excess protein in urine, is a key marker of kidney damage in IgAN, and lowering proteinuria is stron...